Lamivudine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 

HIV

• Adults: 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily.
• Pediatric Patients Aged 3 Months and Older: Administered either once or twice daily. Dose should be calculated on body weight (kg) and should not exceed 300 mg daily. 
• Patients with Renal Impairment: Doses of Lamivudine must be adjusted in accordance with renal function

The most common reported adverse reactions in adults were-

• headache
• nausea
• malaise
• fatigue
• nasal signs and symptoms
• diarrhea
• cough
• fever and cough (children)

Headache	Nausea	Fatigue
Diarrhea	Fever	Coughing

• Co-infected HIV/HBV patients: The emergence of lamivudine-resistant HBV variants has been linked to lamivudine-containing antiretroviral regimens.
• In HIV-1/HCV co-infected patients receiving interferon and ribavirin-based regimens, hepatic decompensation, some fatal, has occurred. Check for treatment-related toxicity. Discontinue Lamivudine as directed by your doctor, and consider reducing or discontinuing interferon alfa, ribavirin, or both.
• In pediatric patients with a history of pancreatitis or other significant risk factors for pancreatitis, use with caution. As clinically indicated, discontinue treatment.
• In patients receiving combination antiretroviral therapy, immune reconstitution syndrome and redistribution/accumulation of body fat have been reported.
• Lower virologic suppression rates and increased risk of viral resistance were observed in pediatric subjects who received Lamivudine oral solution concomitantly with other antiretroviral oral solutions compared with those who received tablets. An all-tablet regimen should be used when possible.